Cholera toxin activates nonconventional adjuvant pathways that induce protective CD8 T-cell responses after epicutaneous vaccination

The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters.
Cholera toxin activates nonconventional adjuvant pathways that induce protective CD8 T-cell responses after epicutaneous vaccination

Irlanda Olvera-Gomez,a,b, Sara E. Hamilton,a Zhengguo Xiao,a,b Carla P. Guimaraes,b, Hidde L. Ploegh,b Kristin A. Hogquist,c, Liangchun Wang,a,4 and Stephen C. Jamesona,c

aCenter for Immunology, Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis MN 55414; and bWhitehead Institute for Biomedical Research, Massachusetts Institute of Technology, Cambridge MA 02142

The ability to induce humoral and cellular immunity via antigen delivery through the unbroken skin (epicutaneous immunization, EPI) has immediate relevance for vaccine development. However, it is unclear which adjuvants induce protective memory CD8 T-cell responses by this route, and the molecular and cellular requirements for priming through intact skin are not defined. We report that cholera toxin (CT) is superior to other adjuvants in its ability to prime memory CD8 T cells that control bacterial and viral challenges. Epicutaneous immunization with CT does not require engagement of classic toll-like receptor (TLR) and inflammasome pathways and, surprisingly, is independent of skin langerin-expressing cells (including Langerhans cells). However, CT adjuvanticity required type-I IFN sensitivity, participation of a Batf3-dependent dendritic cell (DC) population and engagement of CT with suitable gangliosides. Chemoenzymatic generation of CT–antigen fusion proteins led to efficient priming of the CD8 T-cell responses, paving the way for development of this immunization strategy as a therapeutic option.

Most current vaccination methods involve intramuscular or intradermal injection of antigen with suitable adjuvants. However, this approach produces biohazardous needle waste, requires trained personnel for its implementation, and evokes needle phobia, a significant complication that reduces compliance (1). Transdermal or epicutaneous immunization (EPI) strategies aim to avoid these concerns through application of antigen and adjuvants to the unbroken skin. This approach yields both antibody and T-cell responses, including priming of CD8 T cells (2–5). However, little is known about the capacity of EPI to prime memory CD8 T cells capable of protection against pathogen challenge, nor do we understand how adjuvants operate when applied to the intact skin.

Several adjuvants can induce CD8 T-cell priming through EPI. These include toll-like receptor (TLR) agonists such as imiquimod and CpG (6–9), but also the ADP ribosylating bacterial exotoxins such as cholera toxin (CT) and the closely related Escherichia coli heat-labile enterotoxin (LT) (10–12). Application of such toxins to the skin is safe and effective in priming humoral and cellular responses in both mice and humans (4, 10, 13–15). However, previous studies failed to define which adjuvants afford optimal priming of CD8 T-cell responses and durable protective memory. Furthermore, whereas TLR pathways are well characterized, the basis for adjuvanticity of bacterial exotoxins remains mysterious.

Here we compared multiple adjuvants for epicutaneous priming and found that CT was superior in effective induction of CD8 T-cell responses, resulting in protective immunity against pathogen challenge. We find that CT-mediated adjuvanticity occurs in the absence of typical TLR and inflammasome signaling pathways and that langerin-expressing cells (including Langerhans cells) are dispensable for EPI using CT. The adjuvant properties of CT were, however, dependent on host sensitivity to type-1 IFN and expression of monosialylated GM1 gangliosides (to which the CT-B subunit binds) and required a Batf3-dependent dendritic cell (DC) population. Using a unique protein engineering approach to efficiently and site-specifically couple peptides to the catalytic domain of a preassembled holotoxin, we show that a nontoxic version of CT can also be used to prime CD8 T-cell responses epicutaneously. Together, our data indicate that CT is a promising adjuvant for priming protective CD8 T-cell responses through the unbroken skin and that this process uses an unconventional adjuvant mechanism.

Results

Epicutaneous Vaccination Using Cpg and Cholera Toxin Induces a Primary CD8 T-Cell Response. Although several reports describe epicutaneous priming of CD8 T cells (4, 5, 7–9), there is considerable variability in the timing and approach used to determine the T-cell response and the use of skin preconditioning (such as tape stripping and acetone treatment) before immunization. This has made it difficult to compare the efficacy of distinct adjuvants. Hence, we avoided any preconditioning that may disrupt skin barrier function, and simply hydrated the (unshaved) mouse ear skin before brief sequential application of antigen [chicken ovalbumin (OVA) protein or peptide] and a panel of adjuvants (SI Appendix, Fig. S1). As a positive control, we used s.c. immunization with OVA+LPS. To assay early CD8 T-cell responses, we adoptively transferred OVA/Kb–specific T-cell receptor (TCR) transgenic OT-I T cells and monitored the response of these cells 5–6 d following immunization (16).

We tested several TLR agonists and the bacterial exotoxin CT as EPI adjuvants. Several TLR ligands enhanced the response by OT-I cells to OVA, but the TLR9 agonist CpG was especially effective (Fig. L1). Interestingly, CT was similar to CpG in its potency as an EPI adjuvant (Fig. L1). Consistent with previous studies (16, 17), we observed modest expansion of naïve OT-I T cells to EPI OVA protein alone. Both CT and CpG induced extensive carboxyfluorescein succinimidyl ester dilution and up-regulation of activation markers such as CD44, but epicutaneous priming using CT induced enhanced granzyme B expression levels compared with priming with CpG or other adjuvants (SI Appendix, Fig. S1).
EPI Using Cholera Toxin Induces Protective Memory CD8 T Cells. To test priming of protective immunity, we eliminated OT-I adoptive transfer and examined the response of endogenous CD8 T cells. Previous studies characterized CD8 T-cell responses soon after immunization (4–6) and did not determine long-term protective immunity. Hence, we tested the capacity of EPI to induce protective immunity against recombinant Listeria monocytogenes (LM) expressing the K^b-restricted OVA epitope (LM-OVA). Immunity against LM depends on CD8 T cells (18), and hence is a rigorous test of functional priming. Protection against LM-OVA was minimal in response to a single round of EPI, but boosting using the same approach elicited potent protective immunity 30 d following the last immunization (SI Appendix, Fig. S4A). Despite the similarities between Cpg and CT in priming CD8 T-cell responses (Fig. 1A), EPI involving CT as adjuvant produced significantly better protection against LM-OVA, as measured by pathogen clearance in the spleen (Fig. 1B) and liver (SI Appendix, Fig. S4B). Indeed, protection after EPI using OVA/CT was as potent as that induced by vaccination using a live vaccinia-OVA recombinant (VV-OVA) (Fig. 1B). Potentially the response to CT itself could induce LM immunity; however, priming animals with CT alone induced no protection (SI Appendix, Fig. S5). We also tested whether EPI could elicit protection against vaccinia virus infection. Again, whereas prime/boost using Cpg did offer some measure of protection, EPI using CT as adjuvant offered significantly more potent immunity (Fig. 1C). We also explored how EPI priming using different adjuvants affected the size of the antigen-specific memory CD8 T-cell population. Peptide/MHC tetramer enrichment assays were conducted on cells from mice after EPI prime/boost. Whereas EPI using OVA with CT enlarged the OVA/K^b-specific pool, immunization with OVA alone or OVA/Cpg failed to do so (SI Appendix, Fig. S6), presenting a plausible explanation for the differences in protective immunity observed for these groups.

Epicutaneous vaccination involving CT thus generates a functional memory CD8 T-cell population, capable of efficient protection against distinct microbes (LM and vaccinia) assayed at different anatomical sites (spleen and liver for LM-OVA; ovaries for VV-OVA), whereas EPI vaccination using Cpg was significantly less potent.

Adjuvant Effects of CT in EPI Are Independent of Typical TLR and Inflammasome Signaling Pathways, but Do Require Type-I IFN Responses. Our data extend previous reports on the potency of CT and the related exotoxin LT in epicutaneous priming of cellular and humoral responses in mice and humans (12–15), but raised the question of how CT confers its adjuvant effects. Most adjuvants induce “danger” signals to activate the innate immune response through pattern recognition receptors (PRRs) (19). TLRs are a major component of this group, and hence we first tested whether CT requires TLR signaling components to act as an adjuvant. All TLRs, and the related IL-1R, depend on one or both of the adapter proteins Myeloid differentiation primary
response gene 88 (MyD88) and TIR-domain-containing adapter-inducing IFNβ (TRIF) (19). We therefore tested CT-mediated EPI using MyD88/TRIF double-knockout (dKO) hosts. As expected, MyD88/TRIF deficiency led to drastic reduction in the response of transferred OT-I cells to s.c. OVA/LPS (SI Appendix, Fig. S7A), but did not alter the basal OT-I response to EPI using OVA protein alone (SI Appendix, Fig. S7B). The adjuvant effect of CT was unimpaired by MyD88/TRIF deficiency (Fig. 2A), showing that CT does not require defined TLR or IL-1R signaling pathways for its action (Fig. 2A).

Other adjuvants activate the immune response through the NLR or inflammasome pathways, most of which operate through the inflammasome pathway, utilizing nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), most of which signal via the apoptosis-associated speck-like protein containing CARD (ASC) adapter protein (20). However, using ASC−/− mice (Fig. 2A) we determined that ASC deficiency did not impede the effects of CT in augmenting the OT-I T-cell response either. Thus, CT adjuvanticity requires neither prototypical inflammasome activation nor TLR signaling.

An earlier study found that the CD8 T-cell response to apoptotic cell-associated antigens was independent of MyD88/TRIF but required responsiveness to type-I IFN (21). To test for an analogous mechanism in our system, we adoptively transferred OT-I cells into IFNAR−/− (lacking the type-I IFN receptor) or WT control mice and primed with OVA (with or without CT) epicutaneously. The adjuvant effect of CT was lost in IFNAR−/− hosts (Fig. 2B). Because we used WT OT-I CD8 T cells, the type-I IFN sensitivity maps to host cells rather than to the responding CD8 T cells themselves. The adjuvant requirements for CT in EPI and cross-presentation of apoptotic cells (21) may therefore involve similar pathways.

Batf3-Dependent but Not Langerin-Expressing DCs Are Required for EPI Using CT as Adjuvant. Langerhans cells (LCs) are the predominant antigen presenting cells (APC) in the epidermis, and hence likely candidates to be involved in epicutaneous vaccination (17, 22). Furthermore, dermal CD103+ DCs also express langerin (23) and are critical for CD8 T-cell priming following certain skin infections (24). To explore the requirement for langerin-expressing cells in CT-based EPI, we used mice in which the diptheria toxin receptor (DTR) was knocked into the langerin locus (Lang-DTR), allowing for conditional depletion of Langerhans and langerin+ dermal DC using DT injection (25). Earlier studies revealed that elimination of langerin-expressing cells impairs OT-I T-cell priming when OVA protein (without adjuvants) was applied to flank but not ear skin (16); hence, we immunized on the flank for this experimental series. Surprisingly, DT treatment had no significant impact on EPI when using CT as adjuvant (Fig. 3A), suggesting that neither LC or CD103+ DC are required for the epicutaneous adjuvant effects of CT, in contrast

Fig. 2. The adjuvant effect of CT is independent of typical TLR and inflammasome pathways but requires type-I IFN sensitivity. (A) B6, MyD88/TRIF DKO, and ASC KO mice received 2 × 10^5 naïve OT-I cells 1 d before indicated epicutaneous immunization on the ear, and expansion of the OT-I population was determined 5 d after priming. These data are pooled from three independent experiments. (B) B6 or IFNAR KO mice were adoptively transferred with naïve OT-I cells 1 d before the indicated immunization (on ear skin), and expansion of donor OT-I cells was monitored 5 d later. The data are compiled from two independent experiments and similar data were obtained in an additional similar experiment.

Fig. 3. The CT adjuvant effect in epicutaneous immunization involves a Batf3-dependent cell, but occurs in the absence of Langerhans cells. (A) Langerin−/− mice were treated with diptheria toxin to deplete langerin+ cells (“+DT”) or were mock treated. Following adoptive transfer of naïve OT-I cells, the animals were vaccinated, on shaved flank skin, using OVA alone of OVA+CT. Expansion of OT-I cells was determined 6 d later in spleen and lymph nodes. Data were compiled from three independent experiments. (B) B6 and Batf3−/− B6 mice received naïve OT-I cells and 1 d later were EPI primed on the ear skin with OVA alone or OVA+CT, as indicated. The number of OT-I cells was determined 5 d later in the spleen and draining lymph nodes. Data were compiled from three independent experiments.
with previous studies using different EPI approaches (26, 27). We therefore sought to extend our analysis to other DC subsets. The Batf3 transcription factor is needed for generation of two major DC populations: CD103+ DC (including those in the dermis) and CD8α+ DC (28, 29). Following adoptive transfer of OT-I cells into Batf3−/− and control animals, we performed EPI using OVA protein, with or without CT. In contrast to wild-type hosts, the adjuvant effect of CT was almost completely lost in Batf3−/− animals, indicating a Batf3-dependent DC population is essential for this form of EPI (Fig. 3B).

Adjuvant Effects of CT Require Expression of GM1 Gangliosides and Are Enhanced by Antigen–Adjuvant Conjugation. Our finding that TLRs and NLRs were dispensable for CT adjuvanticity prompted further exploration of the manner by which CT engages cells during skin priming.

Both LT and CT are AB5-type toxins, composed of an A subunit and five identical B subunits. The A subunit displays ADP-ribosylation activity, whereas the pentameric B subunit acts as a receptor for cell entry by high-affinity binding to GM1 ganglioside present at the cell surface (10–12). However, one study reported robust intradermal adjuvant activities of both CT and LT occurring in the absence of GM1 binding (30), indicating alternative mechanisms through which CT may provoke the immune response. To determine whether the EPI adjuvant effects of CT require recognition of GM1, we utilized mice (GalT−/−) deficient in the two glycosyltransferases involved in GM1 biosynthesis. Whereas the adjuvant activity of CT was evident in OT-I cells transferred into B6 animals, we saw no adjuvant effect of CT when GalT−/− mice were used as hosts (Fig. 4A). This loss of CT activity might reflect a generalized immune defect in GalT−/− mice; however, when transferred OT-I cells were primed using s.c. LPS/OVA, we observed similar responses in B6 and GalT−/− animals (SI Appendix, Fig. S8), effectively excluding this possibility. The EPI adjuvant properties of CT thus depend on the availability of the gangliosides capable of binding CT-B on host cells, in contrast to studies using intradermal delivery of CT and LT (30).

For both LT and CT, the B-chain pentamer allows intranuclear and intracellular trafficking of the holotoxin, ultimately allowing the A1 subunit to reach the cytosol and lead to cellular intoxication (12). Hence, we postulated that superior induction of the CD8 T-cell response could be elicited by combining the adjuvant effect of CT with concomitant delivery of the antigen to the cytosol for MHC class I presentation. A key element of CT-mediated antigen delivery might derive from the ability of the A1 subunit—and any appended cargo—to be transported across the endoplasmic reticulum (ER) membrane so that it reaches the cytosol and engages the conventional MHC class I processing pathway. To this end, we used a sortase-mediated transpeptidation reaction (31) to couple the OVA peptide (OVApeptide, SIINFEKL) to the CT-A1 subunit in an otherwise intact and correctly folded holotoxin (32). Furthermore, we were able to use this platform to assess the requirement for CT catalytic activity, by generating a similar construct that contains a CT-A1 chain that was mutated to render it enzymatically inactive (CTmut).

The sortase-linked CT-OVApeptide and CT(mut)-OVApeptide were therefore tested for EPI, using the OT-I system. In parallel, we tested sequential administration of OVApeptide and CT (or CT(mut)), maintaining the same molar ratios of peptide to adjuvant. The fused CT-OVApeptide was more effective than the fused CT(mut)-OVApeptide at priming the OT-I response, but both the enzymatically fused complexes were considerably more potent than CT (or CT(mut)) and OVApeptide added separately (Fig. 4B). When higher doses (i.e., a considerable molar excess) of free peptide was tested, the sortaggable versions of both CT and CT(mut) were able to act as adjuvants (SI Appendix, Fig. S9). This finding is in keeping with our previous findings using commercial CT (SI Appendix, Fig. S3). Hence, these data suggest that optimal sensitivity of EPI priming is achieved with CT–antigen fusion and that CT enzymatic activity enhances, but is not absolutely required for adjuvanticity.

Discussion

We examined the mechanism and efficacy of CD8 T-cell priming via epicutaneous immunization on unbroken skin. Whereas several previous studies demonstrate expansion of antigen-specific CD8 T cells after EPI, most focused on responses early after immunization and/or did not evaluate induction of protective responses against pathogens (4–7). Our finding that EPI using the ADP-ribosylating exotoxin CT evokes optimal CD8 T-cell responses (in terms of magnitude, durability, and functional efficacy) parallel work in mice and humans that exploit CT and the TLR7 agonist imiquimod. These discrepancies may, at least in part, relate to the minimal skin pretreatment we used, because several previous studies employed extensive tape stripping (6, 8, 26, 27) and

![Image](https://example.com/image.png)
subsequent acetone treatment (6), which may alter the integrity of the skin and/or properties of APC populations present within it. To ensure eventual applicability, we focused on rapid immunization methods with brief hydration as the only skin pretreatment. With this approach, CT proved superior to other adjuvants tested at elaborating functional CD8 T-cell responses.

Despite numerous reports describing adjuvant activities of CT and LT, the mechanism by which these exotoxins exert such effects was undefined. Here we show that CT adjuvant activity in EPI is independent of major signaling intermediates in the TLR and inflammasome pathways, and that CD8 T-cell priming required sensitivity to type-I IFN by host cells. These findings are reminiscent of the report by Janssen et al., who studied the requirements for CD8 T-cell priming in response to cross-presented apoptotic cells (21). CT induces apoptosis in some epithelial cell lines (33, 34), a trait that may be relevant for adjuvant activity of the toxin and thus account for such mechanistic similarities. However, we observed residual priming activity of enzymatically inactive CT-OVAp, despite the fact that this form of CT has lost its ability to induce cAMP and is correspondingly less toxic (35). Other properties of enzymatically inactive CT, such as its continued ability to direct transfer of the (inactive) A1 subunit from the ER lumen to the cytosol, may be relevant in antigen processing and presentation. Finally, CT binding to GM1 gangliosides induces phenotypic and functional maturation of DCs, suggesting a possible role in APC activation (36). The fact that IFNAR-1 is essential for CT-based EPI is intriguing and suggests that TLR-independent pathways of type-I IFN induction (37) are co-opted in CT adjuvant activity. Whereas further resolution of the mechanisms for CT (and other ADP ribosylating exotoxins) adjuvanticity will be needed, our findings suggest that mechanisms distinct from those engaged by “conventional” adjuvants must be at work. This may be especially relevant for adjuvanticity of exotoxins because the skin is routinely exposed to factors (such as various bacterial TLR agonists), which may desensitize these standard adjuvant pathways.

Epicutaneous immunization has long been assumed to involve antigen capture and/or presentation by Langerhans cells or langerin-expressing CD103+ dermal DC (11, 38) and such populations are indeed required for EPI with protein antigens in the absence of adjuvants (16, 26). However, our current studies revealed that EPI involving CT as an adjuvant was unaffected when langerin-expressing DCs were depleted, leading to the unexpected conclusion that DCs—the canonical epidermal DC population— are not required for T-cell priming through the unbroken skin. Such results could arise from redundancy among cross-presenting DC subsets, as has been seen in some models (39). The CT adjuvant effect was lost in Batf3−/− mice, animals that lack both CD8α+ and dermal CD103+ve DCs (28, 29). DT treatment of langerin−/− and DTR mice causes efficient loss of dermal CD103+ve DCs but not CD8α+ve DCs (16, 25); hence our studies suggest the CD8α+ DC pool are critical for the CT adjuvant effect (although we cannot rule out redundancy between Batf3-dependent DC subsets). Batf3-dependent DCs have been found critical for cross-presentation of antigen (28, 29) and recent studies indicate that the Batf3-dependent CD8α+ DC pool must respond to type-I IFN to mediate effective cross-presentation in tumor models (40, 41). This finding may suggest a mechanistic basis for the observed requirement for IFNAR expression by host cells in EPI priming using CT (Fig. 2B).

The impressive ability of CT as an EPI adjuvant highlights the potential application of this toxin (or related exotoxins) in development of simplified immunization approaches (“vaccination with a bandaid”). Epicutaneous priming using CT and/or LT in mice and humans shows that the approach is effective (at least in terms of antibody responses) and safe (2, 4, 11, 13-15, 26, 42). Our studies demonstrated efficient priming with short term (20 min) exposure to CT, using natural or recombinant versions of the toxin, and revealed partial priming with nontoxic, enzymatically inactive CT-OVAp. This approach lends itself to implementation of cost-effective and convenient immunization methods, while retaining acceptable safety features. In addition, CT itself is an appealing candidate for an antigen as well as an adjuvant: Given the devastating effects of cholera epidemics (as evidenced by recent outbreaks in Haiti) and renewed calls for application of effective vaccination, it is worthwhile noting that epicutaneous application of CT also primes a potent neutralizing antibody response (2, 3, 10). The opportunity to capitalize on the ability of CT to act as a potent CD8 T-cell adjuvant, while simultaneously inducing protection against the toxin itself, makes this approach attractive.

Materials and Methods

Mice. C57BL/6 mice were purchased from The Jackson Laboratory or the National Cancer Institute and were used at 6–8 wk of age. OT-1.PL ( Thy.1+1) mice were generated and maintained at the University of Minnesota. IFNAR KO mice (43) are a kind gift of Matt Mescher (University of Minnesota, Minneapolis). GainT712 ( GainT712 DKO mice, lacking expression of GalNAcT (N-acetylgalactosaminyltransferase) 1 and 2, were obtained from the Mouse Model Core of the Consortium for Functional Glycomics (National Institute of General Medical Sciences) and were maintained by breeding mice deficient for GainT2 (44) and heterozygous for GainT712 (45). Typing of double KO mice was confirmed by peripheral blood cells failing to stain with FITC-CTB (B subunit of CT) (Sigma Aldrich) (35, 46). MyD88/TrifR DKO mice (47) and ASC KO mice (20) were obtained from Shizuo Akira (Osaka University, Osaka, Japan) via Marc Jenkins (University of Minnesota). Lang–DTR mice (25) were obtained from Bernard Malissen (Centre d’immunologie de Marseille Luminy, Marseille), whereas Batf3−/− mice (29) were generously provided by Ken Murphy (Washington University, St. Louis) via Dan Kaplan (University of Minnesota). Animals were maintained under specific pathogen-free conditions, and experimental procedures were approved by the University of Minnesota Institutional Animal Care and Use Committee.

T-Cell Adoptive Transfer. CD44 low CD8 T cells were purified from Thy-1.1+ve OT-1 mice by negative selection using magnetic cell sorting MACS (Miltenyi Biotech) as previously described (16) using MACS microbeads. Cell purity (>90%) was confirmed by flow cytometry. Purified cells (2.5 × 10⁷) were injected into the tail vein of recipient mice.

Epicutaneous Immunization. Immunization was typically on the ear skin, without prior treatment. In some experiments (specified in the text) the flank skin was used, in which case mice were shaved (under anesthetic) at least 2 d before immunization (16). Immunization followed the scheme described in SI Appendix, Fig. S1. Briefly, mice were anesthetized and the skin site hydrated with water (15 min), then OVA protein (500 μg in 25 μL of PBS; Sigma-Aldrich) applied topically for 20 min. After washing with water and air drying, the indicated adjuvants were applied to the same site for 20 min. Unless otherwise indicated, the following doses of adjuvants were used: CT (List Biological Laboratories), 100 μg; Cpg 1826 (Invivogen) 500 μg; Poly IC (Amersham) 200 μg; LPS (Sigma) 10 μg, and imiquimod (3M) 50 μL of 1% cream. The immunization site was extensively washed with water and allowed to dry before the animals recovered. In the case of recombinant CT and/or LT fusion studies, 10 μg of CT or [CT(mut)] was used. For sortase fused OVA-CT/CT(mut), the immunization involved a simple application step. In titration experiments we found similar adjuvant effects using either 10 or 100 μg of commercial CT for EPI on ear skin, but for experimental consistency data with 100 μg CT are shown throughout. The control mice received PBS in place of antigen or adjuvants, as indicated.

CT Fusion Preparation. Details on the preparation of CT fusions with peptides using sortase-mediated transpeptidation reactions have been described elsewhere (32). Briefly, the sortase-recognition motif (LPETG) was cloned between residues Arg192 and Ser193 using site-directed mutagenesis following the manufacturer instructions (Stratagene). This engineered version of CT was expressed and purified as described (32). CT was labeled with GGG51NIFKEL peptide using sortase A from Staphylococcus aureus as described (31). The catalytic inactive mutant of CT (E110D/E112D in subunit A) (48) used in these studies was created by site-directed mutagenesis using engineered CT containing the LPETG motif as template. No difference in expression or efficiency of labeling was detected between the two versions of CTx. The yield of the transpeptidation reactions was higher than 90% as inferred by SDS/PAGE and Coomassie-blue staining.
Flow Cytometry. For adoptive transfer experiments, mice were killed 5–6 d postinmunization. A single-cell suspension from lymph node and spleen was stained with anti-Thy-1.1, anti-CD8, and anti-CD25 or OVA/K+ tetramer to detect transfected OT-I cells. In some studies, cells were stained for CD44 and CD62L or were prepared with Cytofix/Cytoperm (BD Pharmingen), and stained with anti-Granzyme B (Caltag). Antibodies for flow cytometry were obtained from ebioscience or Biolegend. Cells were analyzed using a BD Pharmingen LSR II flow cytometer and data analyzed using FlowJo (TreeStar) software.

Pathogen Protection Assays. Typically, C57BL/6 mice were vaccinated as indicated and received a boost at 30 d later. After an additional 30 d, protective immunity to LM-OVA was monitored, essentially as described previously (49). Briefly, mice were challenge with 10⁵ LM-OVA bacteria via retroorbital injection. At day 5 postinfection, mice were killed and spleens and livers harvested and homogenized to obtain bacterial counts, determined by plating the suspension on LB-streptomycin. The limit of detection was ~100 microorganisms.

For protection against vaccinia virus, vaccinated mice received a challenge with 5 × 10⁶ pfu (plaque forming units) of VV-OVA injected i.v. At day 3 postinfection, ovaries were harvested in PBS and frozen as a single-cell suspension. After two freeze–thaw cycles, the ovary homogenate was incubated at 37 °C for 45 min with 0.2 mg/ml trypsin (Sigma). 143B cells (ATCC) were grown to confluency. Dilutions of the ovary homogenate were added in duplicate to the cellular monolayer and left for 2 d. Plaques were counted and total viral load per ovaries was calculated.

Tetramer Enrichment Assays. Mice were primed and boosted by EPI, as described in Fig. 2. At 30 d following boosting, spleen and lymph nodes were combined and subjected to OVA/K+ tetramer enrichment, as described previously (50). Absolute numbers of OVA/K+ tetramer binding CD8 T cells were determined.

In Vivo Depletion of Lcs. Depletion of langerin+ cells was performed in Lang- DTR mice (25) by i.p. injection of 1 μg DT (List Biological Laboratories) at day −1 or, in some experiments, days −4 and −1, relative to the day of vaccination, as described previously (16).

Statistics. Data were transformed to log₁₀ and an unpaired two-tailed Student’s t test was used to determine significance with Prism software (GraphPad).

ACKNOWLEDGMENTS. We thank Shizuo Akira, Bernard Malissen, Kenneth Murphy, Dan Kaplan, Matt Mescher, and Marc Jenkins for providing mouse strains; Laura Bursch for advice and assistance; and the past and present S.C.J. and K.A.H. laboratory members for input. These studies were supported by Grant U01 AI07380 from the National Institutes of Health (to S.C.J. and K.A.H.).